Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions - PubMed

Affiliations

• PMID: 33592199
• DOI: 10.1016/j.lfs.2021.119220

Review

Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions

Samar H Gerges et al. Life Sci. 2021.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a disorder of excessive fat accumulation in the liver, known as steatosis, without alcohol overconsumption. NAFLD can either manifest as simple steatosis or steatohepatitis, known as non-alcoholic steatohepatitis (NASH), which is accompanied by inflammation and possibly fibrosis. Furthermore, NASH might progress to hepatocellular carcinoma. NAFLD and NASH prevalence is in a continuous state of growth, and by 2018, NAFLD became a devastating metabolic disease with a global pandemic prevalence. The pathophysiology of NAFLD and NASH is not fully elucidated, but is known to involve the complex interplay between different metabolic, environmental, and genetic factors. In addition, unhealthy dietary habits and pre-existing metabolic disturbances together with other risk factors predispose NAFLD development and progression from simple steatosis to steatohepatitis, and eventually to fibrosis. Despite their growing worldwide prevalence, to date, there is no FDA-approved treatment for NAFLD and NASH. Several off-label medications are used to target disease risk factors such as obesity and insulin resistance, and some medications are used for their hepatoprotective effects. Unfortunately, currently used medications are not sufficiently effective, and research is ongoing to investigate the beneficial effects of different drugs and phytochemicals in NASH. In this review article, we outline the different risk factors and pathophysiological mechanisms involved in NAFLD, diagnostic procedures, and currently used management techniques.

Keywords: Adipose tissue; Diagnosis; Fibrosis; Insulin resistance; Management; Non-alcoholic steatohepatitis; Steatosis.

Similar articles

• Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.

  Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Bessone F, et al. Aliment Pharmacol Ther. 2018 Nov;48(9):892-913. doi: 10.1111/apt.14952. Epub 2018 Sep 7. Aliment Pharmacol Ther. 2018. PMID: 30194708 Review.

• Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.

  Milić S, Lulić D, Štimac D. Milić S, et al. World J Gastroenterol. 2014 Jul 28;20(28):9330-7. doi: 10.3748/wjg.v20.i28.9330. World J Gastroenterol. 2014. PMID: 25071327 Free PMC article. Review.

• Non-alcoholic fatty liver disease in 2016.

  Townsend SA, Newsome PN. Townsend SA, et al. Br Med Bull. 2016 Sep;119(1):143-56. doi: 10.1093/bmb/ldw031. Epub 2016 Aug 19. Br Med Bull. 2016. PMID: 27543499 Free PMC article. Review.

• FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.

  Tillman EJ, Rolph T. Tillman EJ, et al. Front Endocrinol (Lausanne). 2020 Dec 14;11:601290. doi: 10.3389/fendo.2020.601290. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33381084 Free PMC article. Review.

• The diagnosis and treatment of non-alcoholic fatty liver disease.

  Altinbas A, Sowa JP, Hasenberg T, Canbay A. Altinbas A, et al. Minerva Gastroenterol Dietol. 2015 Sep;61(3):159-69. Epub 2015 Jun 17. Minerva Gastroenterol Dietol. 2015. PMID: 26080905 Review.

Cited by

• Association between the peripheral neutrophil-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes.

  Zhu N, Song Y, Zhang C, Wang K, Han J. Zhu N, et al. Front Med (Lausanne). 2023 Nov 6;10:1294425. doi: 10.3389/fmed.2023.1294425. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38020132 Free PMC article.

• Beneficial Effects of Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles on Hepatic Injury Induced High Glycemic Index Diet: A Preclinical Study.

  Aguiar AJFC, de Queiroz JLC, Santos PPA, Camillo CS, Serquiz AC, Costa IS, Oliveira GS, Gomes AFT, Matias LLR, Costa ROA, Passos TS, Morais AHA. Aguiar AJFC, et al. Int J Mol Sci. 2021 Sep 15;22(18):9968. doi: 10.3390/ijms22189968. Int J Mol Sci. 2021. PMID: 34576130 Free PMC article.

• Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis.

  Jin D, Jin S, Zhou T, Cui Z, Guo B, Li G, Zhang C. Jin D, et al. Front Public Health. 2024 Jan 4;11:1295165. doi: 10.3389/fpubh.2023.1295165. eCollection 2023. Front Public Health. 2024. PMID: 38259755 Free PMC article.

• Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease.

  Liu L, Geng Y, Xiong C. Liu L, et al. Ann Med. 2023;55(2):2255825. doi: 10.1080/07853890.2023.2255825. Ann Med. 2023. PMID: 37708866 Free PMC article. Review.

• Non-alcoholic fatty liver disease: relation to juvenile obesity, lipid profile, and hepatic enzymes.

  Altalebi RR, Al-Hussaniy HA, Al-Tameemi ZS, Al-Zobaidy MA, Albu-Rghaif AH, Alkuraishy HM, Hedeab GM, Azam F, Al-Samydai AM, Naji MA. Altalebi RR, et al. J Med Life. 2023 Jan;16(1):42-47. doi: 10.25122/jml-2022-0091. J Med Life. 2023. PMID: 36873135 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information